Seres Therapeutics (MCRB) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tvardi Therapeutics is the larger company by market cap ($13.2 million vs $12.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MCRB | TVRD |
|---|---|---|
| Share price | $1.24 | $0.9893 |
| Market cap | $12.64M | $13.22M |
| 1-day change | -6.77% | +4.57% |
| YTD return | — | -76.99% |
| 1-year return | — | -74.76% |
| 5-year return | — | -99.79% |
| EPS (TTM) | $-5.01 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $789.00K | — |
| Net income (latest FY) | $5.70M | $-18.21M |
| Operating margin | -11910.14% | — |
| Net margin | 721.93% | — |
| 52-week high | $18.86 | $5.69 |
| 52-week low | $1.20 | $0.773 |
| Distance from 52-week high | -93.43% | -82.61% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1270.97% | +835.00% |
| Average volume | 74.83K | 235.95K |
| Shares outstanding | 10.20M | 13.36M |
| Employees | 66 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
MCRB vs TVRD FAQ
Which is bigger, Seres Therapeutics or Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $13.22M compared with $12.64M for Seres Therapeutics (MCRB).
Are Seres Therapeutics and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.